PhRMA Clinical Trial Code: Disclosure Edition
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.